Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis

Stefan Cordes, Angela Dispenzieri, Martha Lacy, Suzanne R. Hayman, Francis K. Buadi, David M Dingli, Shaji K Kumar, William Hogan, Morie Gertz

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

BACKGROUND: The current study was conducted to determine characteristics distinguishing the 10-year survivor group in patients with systemic immunoglobulin light chain (AL) amyloidosis who underwent autologous stem cell transplantation (SCT). METHODS: The study group included all 74 patients with AL amyloidosis who underwent high-dose melphalan treatment supported by autologous SCT since the beginning of the Mayo Clinic's SCT program until prior to August 2001. RESULTS: A total of 32 patients (43%) patients survived for > 10 years. Statistically significant baseline differences in the 10-year survivor group included: 1) the number of organs involved; 2) septal thickness; 3) total cholesterol; and 4) urine total protein. The number of organs involved was the only predictor found on multivariable analysis. Depth of the response to therapy, as measured by the lowest posttransplantation serum free light chain level, was found to be the most significant indicator of durability of response. CONCLUSIONS: Autologous SCT can offer durable benefit for patients with AL amyloidosis. The number of organs involved offers the greatest pretreatment prognostic value, whereas the lowest posttransplantation serum free light chain level offers the best posttreatment prognostic value.

Original languageEnglish (US)
Pages (from-to)6105-6109
Number of pages5
JournalCancer
Volume118
Issue number24
DOIs
StatePublished - Dec 15 2012

Fingerprint

Immunoglobulin Light Chains
Stem Cell Transplantation
Amyloidosis
Survival
Survivors
Light
Melphalan
Serum
Cholesterol
Urine
Therapeutics
Proteins

Keywords

  • amyloidosis complications
  • amyloidosis therapy
  • humans
  • immunoglobulin light chain
  • prognosis
  • stem cell transplantation
  • therapeutic use of alkylating agents

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis. / Cordes, Stefan; Dispenzieri, Angela; Lacy, Martha; Hayman, Suzanne R.; Buadi, Francis K.; Dingli, David M; Kumar, Shaji K; Hogan, William; Gertz, Morie.

In: Cancer, Vol. 118, No. 24, 15.12.2012, p. 6105-6109.

Research output: Contribution to journalArticle

@article{817cbe06f9c141319e6335a8c859fa13,
title = "Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis",
abstract = "BACKGROUND: The current study was conducted to determine characteristics distinguishing the 10-year survivor group in patients with systemic immunoglobulin light chain (AL) amyloidosis who underwent autologous stem cell transplantation (SCT). METHODS: The study group included all 74 patients with AL amyloidosis who underwent high-dose melphalan treatment supported by autologous SCT since the beginning of the Mayo Clinic's SCT program until prior to August 2001. RESULTS: A total of 32 patients (43{\%}) patients survived for > 10 years. Statistically significant baseline differences in the 10-year survivor group included: 1) the number of organs involved; 2) septal thickness; 3) total cholesterol; and 4) urine total protein. The number of organs involved was the only predictor found on multivariable analysis. Depth of the response to therapy, as measured by the lowest posttransplantation serum free light chain level, was found to be the most significant indicator of durability of response. CONCLUSIONS: Autologous SCT can offer durable benefit for patients with AL amyloidosis. The number of organs involved offers the greatest pretreatment prognostic value, whereas the lowest posttransplantation serum free light chain level offers the best posttreatment prognostic value.",
keywords = "amyloidosis complications, amyloidosis therapy, humans, immunoglobulin light chain, prognosis, stem cell transplantation, therapeutic use of alkylating agents",
author = "Stefan Cordes and Angela Dispenzieri and Martha Lacy and Hayman, {Suzanne R.} and Buadi, {Francis K.} and Dingli, {David M} and Kumar, {Shaji K} and William Hogan and Morie Gertz",
year = "2012",
month = "12",
day = "15",
doi = "10.1002/cncr.27660",
language = "English (US)",
volume = "118",
pages = "6105--6109",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "24",

}

TY - JOUR

T1 - Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis

AU - Cordes, Stefan

AU - Dispenzieri, Angela

AU - Lacy, Martha

AU - Hayman, Suzanne R.

AU - Buadi, Francis K.

AU - Dingli, David M

AU - Kumar, Shaji K

AU - Hogan, William

AU - Gertz, Morie

PY - 2012/12/15

Y1 - 2012/12/15

N2 - BACKGROUND: The current study was conducted to determine characteristics distinguishing the 10-year survivor group in patients with systemic immunoglobulin light chain (AL) amyloidosis who underwent autologous stem cell transplantation (SCT). METHODS: The study group included all 74 patients with AL amyloidosis who underwent high-dose melphalan treatment supported by autologous SCT since the beginning of the Mayo Clinic's SCT program until prior to August 2001. RESULTS: A total of 32 patients (43%) patients survived for > 10 years. Statistically significant baseline differences in the 10-year survivor group included: 1) the number of organs involved; 2) septal thickness; 3) total cholesterol; and 4) urine total protein. The number of organs involved was the only predictor found on multivariable analysis. Depth of the response to therapy, as measured by the lowest posttransplantation serum free light chain level, was found to be the most significant indicator of durability of response. CONCLUSIONS: Autologous SCT can offer durable benefit for patients with AL amyloidosis. The number of organs involved offers the greatest pretreatment prognostic value, whereas the lowest posttransplantation serum free light chain level offers the best posttreatment prognostic value.

AB - BACKGROUND: The current study was conducted to determine characteristics distinguishing the 10-year survivor group in patients with systemic immunoglobulin light chain (AL) amyloidosis who underwent autologous stem cell transplantation (SCT). METHODS: The study group included all 74 patients with AL amyloidosis who underwent high-dose melphalan treatment supported by autologous SCT since the beginning of the Mayo Clinic's SCT program until prior to August 2001. RESULTS: A total of 32 patients (43%) patients survived for > 10 years. Statistically significant baseline differences in the 10-year survivor group included: 1) the number of organs involved; 2) septal thickness; 3) total cholesterol; and 4) urine total protein. The number of organs involved was the only predictor found on multivariable analysis. Depth of the response to therapy, as measured by the lowest posttransplantation serum free light chain level, was found to be the most significant indicator of durability of response. CONCLUSIONS: Autologous SCT can offer durable benefit for patients with AL amyloidosis. The number of organs involved offers the greatest pretreatment prognostic value, whereas the lowest posttransplantation serum free light chain level offers the best posttreatment prognostic value.

KW - amyloidosis complications

KW - amyloidosis therapy

KW - humans

KW - immunoglobulin light chain

KW - prognosis

KW - stem cell transplantation

KW - therapeutic use of alkylating agents

UR - http://www.scopus.com/inward/record.url?scp=84870699271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870699271&partnerID=8YFLogxK

U2 - 10.1002/cncr.27660

DO - 10.1002/cncr.27660

M3 - Article

VL - 118

SP - 6105

EP - 6109

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 24

ER -